Regulus Therapeutics Inc RGLS

NAS: RGLS | ISIN: US75915K2006   26/04/2024
2,420 USD (+6,61%)
(+6,61%)   26/04/2024

21 maart 2024 · Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates · Persbericht

12 maart 2024 · Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity · Persbericht

12 maart 2024 · Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

2 januari 2024 · Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

9 november 2023 · Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates · Persbericht

2 november 2023 · Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

19 oktober 2023 · Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

20 september 2023 · Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

13 september 2023 · Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

5 september 2023 · Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences · Persbericht

23 augustus 2023 · Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023 · Persbericht

8 augustus 2023 · Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates · Persbericht

2 augustus 2023 · Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference · Persbericht

18 juli 2023 · Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference · Persbericht

27 juni 2023 · Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

23 juni 2023 · Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors · Persbericht

20 juni 2023 · Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital · Persbericht

12 juni 2023 · Regulus Therapeutics Strengthens Research & Development Leadership · Persbericht

16 mei 2023 · Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

11 mei 2023 · Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates · Persbericht

Mijn selecties